- About Us
- Services & Solutions
- Novel Technology Platform
- Bioconjugation Discovery
- Bioconjugation Process Development
- Analytical Development
- Formulation and DP Development
- GMP mAb Intermediate and Conjugation Manufacturing
- GMP Formulation, Fill and Lyophilization
- Payload and Linker R&D and Manufacturing
- Ready-Made Payloads & Linkers
- WuXi XDC Singapore Site
- Investor Relations
- News & Resources
WuXi Biologics
Offering End-to-End Solutions
- About Us
About Us - Services & SolutionsAbout Us
- Investor RelationsAbout Us
- News & ResourcesAbout Us
Scientific Poster Download
Poster modified on 16/04/2026
WuXiTecan-2 a hydrophilic exatecan linker-payload for dual-payload ADC discovery
WuXiTecan-2 is a proprietary hydrophilic exatecan payload–linker with enhanced hydrophilicity and superior plasma stability, making it suitable for both single and dual-payload ADC development.
WuXiTecan-2 demonstrated favorable pharmacokinetic (PK) profiles in both rodent and cynomolgus monkey studies, characterized by minimal deconjugation. WuXiTecan-2(DAR8) ADCs were well tolerated at the highest dose tested in cyno studies (45mg/kg, Q3Wx3).
In vivo, WuXiTecan-2 ADCs showed improved efficacy compared with DXd-based payloads, efficacy comparable to other exatecan payload–linkers in clinical development, and enhanced, more durable anti-tumor activity in dual-payload ADC (dp-ADC) formats.
Further linker optimization can improve the safety profile of dual-payload ADCs.
Discuss This Poster
To discuss the data in this poster, please complete the form on the following page to connect with our experts.
Notice:
You are leaving WuXi Biologics Website, after which our Privacy Notice will not apply. Please keep it in mind the protection of your privacy. Are you willing to proceed?